0 untranslated region (3 0 UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3 0 UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS variant-positive EOC patients. As this variant seems to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival. EOC patients with complete clinical data were genotyped for the KRAS variant and analyzed for outcome (n ¼ 536), response to neoadjuvant chemotherapy (n ¼ 125) and platinum resistance (n ¼ 306). Outcome was separately analyzed for women with known BRCA mutations (n ¼ 79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were used to confirm altered sensitivity to chemotherapy associated with the KRAS variant. Finally, the KRAS variant was directly targeted through small-interfering RNA/miRNA oligonucleotides in cell lines and survival was measured. Postmenopausal EOC patients with the KRAS variant were significantly more likely to die of ovarian cancer by multivariate analysis (hazard ratio ¼ 1.67, 95% confidence interval: 1.09 --2.57, P ¼ 0.019, n ¼ 279). Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio ¼ 3.18, confidence interval: 1.31 --7.72, P ¼ 0.0106, n ¼ 291). In addition, direct targeting of the KRAS variant led to a significant reduction in EOC cell growth and survival in vitro. These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this study supports the hypothesis that these tumors have continued dependence on such 3 0 UTR lesions, and that direct targeting may be a viable future treatment approach.
INTRODUCTION
Epithelial ovarian cancer (EOC) is the second most common female pelvic reproductive organ cancer in the United States, and carries the highest mortality in this category in the Western world. It is the fifth overall leading cause of cancer death in females in the United States, with 13 850 women dying from this disease yearly. 1 Despite multiple new approaches to treatment, the high rates of death from EOC have remained largely unchanged for many years, with a 5-year overall survival of only 30 --39%. 2 The standard chemotherapy regimen to treat EOC currently used is carboplatin and paclitaxel, 3 based on prospective randomized trials. 4 --6 Although some patients are initially resistant to platinum-based chemotherapy (referred to as 'platinum resistant'), developing recurrence within 6 months of treatment, it is the first line treatment given to all EOC patients. An improved understanding of the fundamental biological differences in EOC tumors that could explain platinum resistance among EOC patients would allow a more rational selection of treatments. 2 --4 MicroRNAs (miRNAs) are a class of 22-nucleotide non-coding RNAs that are aberrantly expressed in virtually all cancer types, in which they can function as a novel class of oncogenes or tumor suppressors. 5 In EOC, in addition to distinguishing normal ovarian tissue from malignant ovarian tissue, 6 ,7 miRNA expression patterns have been shown to be important in EOC pathogenesis 8, 9 and are associated with altered EOC patient outcome 10 and response to treatment.
11 miRNA expression differences have also been associated with chemotherapy and platinum resistance in EOC.
Additional insight into the importance of miRNAs in cancer has come from the discovery of inherited single-nucleotide polymorphisms that disrupt miRNA coding sequences 13 and miRNA-binding sites in the 3 0 untranslated regions (3 0 UTRs) of oncogenes. 12, 13 An example of such a functional variant is rs61764370, referred to as the KRAS variant, which is located in the KRAS 3 0 UTR in a let-7 miRNA complementary site. This variant has been reported to be a genetic marker of risk for lung cancer, 13 ovarian cancer (especially for women from hereditary breast and ovarian cancer families 14 ) and triple-negative breast cancer (TNBC). 15 In addition, this variant may have an association with BRCA1, being enriched in both ovarian cancer patients from BRCA1 hereditary breast and ovarian cancer families 14 and breast cancer patients who carry pathogenic BRCA1 mutations. 16 The KRAS variant has also been shown to be associated with altered miRNA and gene expression in tumors, 13, 17 to act as a biomarker of poor outcome in head and neck cancer 17 and to be a biomarker of resistance to targeted chemotherapy in colon cancer. 18 These findings suggest a continued functional role of the KRAS variant in tumors, and an association with aggressive tumor biology and poor cancer-specific outcome.
Here, we evaluate the potential of the KRAS variant to act as a biomarker of outcome in EOC in both the presence and the absence of deleterious BRCA mutations. We also investigate the potential cause of altered outcome in KRAS-variant EOC patients by studying the response to neoadjuvant platinum-based chemotherapy, assessing platinum resistance and evaluating EOC tumor gene expression. Finally, we test the hypothesis that directly targeting of this gain-of-function KRAS variant could reduce cell growth and survival in EOC cell lines with this lesion.
RESULTS

Overall survival in EOC patients with the KRAS variant
We evaluated the association of the KRAS variant with overall survival in 454 EOC patients either tested and negative or untested for deleterious BRCA mutations. For the entire cohort, the KRAS variant did not predict worse survival by Kaplan --Meier analysis. Yet based on previous evidence that the KRAS variant is most strongly associated with postmenopausal ovarian cancer, 13 we evaluated survival in women over 52 years of age (n ¼ 279), an age considered to be an appropriate surrogate for menopausal status. By Kaplan --Meier analysis, survival was significantly reduced in postmenopausal KRAS-variant EOC patients (n ¼ 59) compared with non-variant EOC patients (n ¼ 220, Figure 1 , logrank P ¼ 0.0399, non-KRAS-variant survival median 60 months, KRAS-variant survival median 34 months). When other variables including age, stage, grade, histology and treatment center were included with KRAS-variant status in a multivariate Cox proportional hazards regression model, the KRAS variant was a statistically significant predictor of reduced overall survival for postmenopausal women with EOC (Table 1) ; the hazard ratio for the KRAS variant was 1.67 (95% confidence interval: 1.09 --2.57, P ¼ 0.019).
We next evaluated the association of the KRAS variant with survival in a separate cohort of EOC patients carrying deleterious BRCA1 or BRCA2 mutations (n ¼ 79). EOC patients carrying BRCA mutations were significantly younger than EOC patients without BRCA mutations (52.7 vs 60.8 years of age, Po0.0001). In addition, EOC patients with BRCA mutations had a significantly longer median survival by multivariate analysis controlling for age, stage, grade and histology than did EOC patients without BRCA mutations (120 vs 52 months, P ¼ 0.0036). There was not a significant difference in survival between EOC patients with BRCA mutations with or without the KRAS variant in a multivariate analysis using a multivariate Cox proportional hazards regression model (Supplementary Table 1 , KRAS-variant hazard ratio ¼ 0.75, 95% confidence interval: 0.21 --2.72, P ¼ 0.66). There were too few patients to evaluate the impact of the KRAS variant on survival in postmenopausal EOC patients harboring deleterious BRCA mutations.
The KRAS variant and platinum resistance To gain insight into potential reasons for the reduced survival in postmenopausal KRAS variant-positive EOC patients, we evaluated the association of KRAS-variant positivity with response to platinum-based chemotherapy, the standard first-line chemotherapy in the treatment of EOC. We first evaluated all women with EOC who were treated at the Yale-New Haven Hospital (YNHH) with neoadjuvant platinum-containing chemotherapy followed by surgical cytoreduction (n ¼ 116), and used residual disease after surgery (cytoreduction) as a surrogate marker of patient response to chemotherapy. We found that 15.4% of KRAS-variant patients (n ¼ 26) were suboptimally cytoreduced (41 cm of residual disease after surgery), compared with only 3.33% of non-variant patients (n ¼ 90) (Figure 2 , P ¼ 0.044). The KRAS variant was also significantly associated with suboptimal cytoreduction after neoadjuvant chemotherapy and surgery in a multivariate logistic regression model controlling for age, stage, grade and histology (Supplementary Table 2 , odds ratio ¼ 9.36, 95% confidence interval: 1.34 --65.22, P ¼ 0.024). The KRAS variant predicts significantly worse overall survival for postmenopausal ovarian cancer patients over 52 years of age. Overall survivals for ovarian cancer patients with (n ¼ 59) and without (n ¼ 220) the KRAS variant are compared using the Kaplan --Meier analysis. Outcome is significantly worse for KRAS variantpositive EOC patients over 52 years of age by log-rank test (P ¼ 0.0399). To determine whether the cause of poor response to neoadjuvant platinum-based chemotherapy seen in KRAS-variant EOC patients was due to resistance to platinum chemotherapy, we evaluated platinum resistance in all EOC patients treated adjuvantly with platinum chemotherapy without documented BRCA mutations with available response data (n ¼ 291). We found that platinum resistance (disease recurrence within 6 months of receiving platinum-based chemotherapy) was significantly more likely in KRAS variant-positive EOC patients than in non-KRASvariant EOC patients (16.67 vs 7.56%, P ¼ 0.034). The KRAS variant was a statistically significant predictor for platinum resistance for EOC patients of all ages in a multivariate logistic regression analysis controlling for residual disease remaining after cytoreductive surgery, stage, histology, age and grade (Table 2 , odds ratio ¼ 3.18, 95% confidence interval: 1.31 --7.72, P ¼ 0.0106).
Gene expression in KRAS-variant ovarian tumors Gene expression studies were performed on a small cohort of ovarian cancer patients who had fresh-frozen tissue available (Brescia cohort), and compared between seven serous EOC samples with the KRAS variant and nine without the variant (n ¼ 16). We found that within this cohort, in postmenopausal EOC patients over 52 years of age with EOC (n ¼ 10), a gene signature previously found to be associated with KRAS variant-associated TNBC 15 was also upregulated in KRAS variant-associated EOC ( Figure 3a ). In addition, again similar to the previous analysis in TNBC, we found overexpression of KRAS-associated downstream pathways in EOC KRAS-variant tumors, consistent with 'KRAS addiction' 19 ( Figure 3b ). Using previous analyses of gene expression data identifying platinum-resistant vs sensitive signatures, 20 we tested and found that KRAS-variant EOC samples had a lower carboplatin sensitivity signature compared with non-variant EOC samples (Figure 3c ). In agreement with findings in previous studies showing that the activation of the AKT pathway was frequently involved in platinum resistance, we found that AKT3 was one of the most significantly upregulated transcripts in KRAS-variant EOC tumors (Figure 3d ).
Although miRNA expression data were not available on tumor samples, we did compare expression of let-7b miRNA that had previously been shown to be altered in KRAS variant-positive lung tumors 13 and triple-negative breast tumors, 15 in two cell lines with the KRAS variant (BG-1 and IGROV1) compared with a non-variant line (CAOV3). We found that let-7b was significantly lower in cells with the KRAS variant ( Supplementary Figure 1) , consistent with our previous results, and a recent publication showing the association of low levels of this miRNA and poor ovarian cancer outcome. 21 The KRAS variant and chemosensitivity in ovarian cancer cell lines To confirm altered chemosensitivity in the presence of the KRAS variant, we used EOC cell lines with and without the KRAS variant and tested their sensitivity to different chemotherapeutic agents. We tested a cell line that is KRAS variant positive/BRCA wild-type (BG1), a non-variant/BRCA wild-type cell line (CAOV3) and a cell line KRAS-variant positive/BRCA1 mutant (IGR-OV1). We found that the KRAS-variant line, BG1, was significantly resistant to carboplatin (Po0.04) and carboplatin/paclitaxel combination chemotherapy (Po0.0001) compared with CAOV3, the cell line without the KRAS variant. In contrast, IGROV1, the cell line with the KRAS variant and a deleterious BRCA1 mutation, was not resistant to these agents compared with CAOV3 ( Figure 4 ). These findings are in agreement with our clinical findings that the KRAS variant is associated with platinum resistance, but perhaps not in the presence of deleterious BRCA mutations.
We additionally evaluated agents frequently used as secondline therapy for patients who have failed carboplatin/paclitaxel chemotherapy, including doxorubicin, topotecan and gemcitabine. We found that the KRAS-variant line, BG1, was significantly resistant to each of these agents compared with CAOV3, the nonvariant cell line (Table 3 ).
Targeting the KRAS variant As previous 15 and current gene expression findings suggested a continued use of KRAS signaling in KRAS variant-associated tumors, we evaluated the impact of directly targeting this 3 0 UTR lesion. We designed small-interfering RNA (siRNA)/miRNA-like complexes that could directly bind the altered allele in KRASvariant transcripts, but not in non-KRAS-variant transcripts (Supplementary Figure 2) . We found that transfecting these oligonucleotide duplexes that target the KRAS variant caused a significant decrease in cell survival in the KRAS variant carrying BG1 cell line (Po0.001), but had no effect in CAOV3 (Figure 5a ) or SKOV3 (data not shown), two non-variant EOC cell lines. This finding was concordant with a moderate decrease in KRAS protein levels by western blot in BG1, but not in CAOV3 (Figure 5b ) or SKOV3 (data not shown) after treatment.
DISCUSSION
Our data indicate that the KRAS variant is a biomarker of poor outcome for postmenopausal women (over 52 years of age) with EOC. The poor outcome in KRAS variant-associated ovarian cancer may be due to the association of the KRAS variant with resistance 
to platinum-based chemotherapy, based on a worse response to neoadjuvant platinum-based chemotherapy, and significantly increased platinum resistance in adjuvantly treated EOC patients with the KRAS variant.
The biological differences between KRAS-variant EOC and nonvariant EOC tumors are supported by gene expression data , which suggests KRAS addiction and AKT-mediated platinum resistance in KRAS-variant-associated EOC. Platinum resistance was further confirmed in vitro in an ovarian cancer cell line with the KRAS variant as compared with a non-variant line. Finally, evidence for the continued dependence of KRAS variant-associated EOC on this germline lesion was shown through direct targeting of this mutation, which led to significant growth and survival inhibition in a KRAS-variant EOC cell line vs non-variant EOC lines. The association of the KRAS variant with poor survival specifically for postmenopausal women could be due to underlying biology associated with this variant or unknown confounding effects in these studies. Supporting the hypothesis that this finding reflects underlying biology, the KRAS variant is associated with postmenopausal ovarian cancer 14 (Supplementary Table 3) , with a median age of diagnosis near 59 years of age. It is known that relative survival varies by age, with older women twice as likely to die within 5 years of diagnosis of EOC, supporting the hypothesis that postmenopausal women may have biologically different tumors than younger women. 22 In addition, the KRAS variant has been shown to be a biomarker of TNBC risk specifically in premenopausal women, aged o52 years. 15 This may indicate that similar to other miRNA-binding site variants, the role of the KRAS variant in cancer risk and biology in different tissues may depend on miRNA expression alterations in response to physiologic conditions, 23 in this case, menopause. This would suggest that women with the KRAS variant may be first at risk for breast cancer and then subsequently at risk for developing postmenopausal ovarian cancer. Studies are ongoing to test this hypothesis.
Our findings that the KRAS variant does not predict for poor outcome in our cohort of EOC patients with known deleterious BRCA mutations may be partially explained by the fact that BRCA mutations are associated with platinum sensitivity, and that this effect may act downstream of any resistance caused or exacerbated by the KRAS variant to platinum agents. The younger patients in our cohorts could have had undocumented deleterious BRCA mutations, or may also have had other subtypes of ovarian cancer seen more frequently in younger women, such as borderline tumors, and were perhaps misdiagnosed. Although our data sets were extremely well clinically annotated, a weakness of our study is that BRCA status was not obtained on all of our EOC patients, and although pathology reports were available, tumor tissue was not available for re-review. This does highlight the importance of using clinically well-annotated data sets to study functional markers such as the KRAS variant, to allow appropriate interpretation of the results. A recent study that failed to find the association of the KRAS variant with poor outcome and resistance to therapy in EOC 24 used ovarian collections used for genomewide association studies that had very limited clinical information, and important factors such as BRCA status and ovarian cancerspecific survival were not available nor included in their analyses.
The association of the KRAS variant with resistance to platinumbased chemotherapy for non-BRCA mutant EOC patients is perhaps not surprising, as KRAS pathway disruption has been associated with platinum resistance in ovarian cancer 20, 25 and in several other cancers. 26, 27 The KRAS variant has been previously shown to lead to KRAS and associated downstream pathway overexpression in TNBC, 15 which concords with our gene expression findings in this study in EOC, even with a small number of tumors available for study. It is interesting that similar gene mis-expression patterns were found in two different types of KRAS variant-associated tumors, suggesting that these tumors, regardless of tissue of origin, perhaps use similar pathways in oncogenesis. It would be important and interesting to validate these findings in larger gene expression data sets and additional tumor types, work that is ongoing. Perhaps most intriguing is the finding that direct targeting of the KRAS-variant lesion in KRAS variant-associated EOC cell lines leads to significantly enhanced cell death and a reduction in KRAS levels. Although there is considerable work to be done to understand the mechanisms behind these findings, they do suggesting continued critical dependence of these tumors on this single, non-coding germline lesion. Although there has been a significant effort to tailor cancer treatment by measuring tumor gene expression and determining tumor-acquired mutations, there are few, if any, germline variants that have previously been shown to be critical targets for therapy in cancer.
There is still work to be done to better define the mechanisms of KRAS variant-associated platinum resistance and its potential as a future target for therapy in EOC. However, this study supports the conclusions that the KRAS variant is a functional cancer mutation that is important in ovarian cancer, and that the KRAS variant allows meaningful subclassification of the ovarian tumors it is associated with. Hopefully, these findings can ultimately be used to improve ovarian cancer patient outcome.
MATERIALS AND METHODS
Overall survival analysis cohorts
Complete clinical data and DNA from women diagnosed with EOC without known BRCA mutations were included from the following three institutions under individual International Review Board approvals. All protocols accrued patients prospectively at the time of their diagnosis to avoid selection bias. References indicate previous detailed descriptions of these patients: (1) Turin, Italy #1 (n ¼ 197), 28 (2) Brescia, Italy #2 (n ¼ 59) and 14 Table 3) .
Documented BRCA mutant EOC cases with known outcome were collected from the following two institutions: (1) the YNHH (n ¼ 17) and (2) the City of Hope Comprehensive Cancer Center (n ¼ 62) (Supplementary Table 4 ).
As not all stage I ovarian cancer patients receive adjuvant chemotherapy, when substage information was not available for patients with stage 1 tumors, these patients were excluded from the analysis. Otherwise, stage 1B and 1C tumors were included with stages 2 --4. To minimize inadvertent inclusion of borderline tumors, tumors with an unknown grade were excluded from this analysis. For women treated with neoadjuvant chemotherapy, the date of pathological diagnosis was considered the start date of treatment. For women treated with adjuvant chemotherapy, the date of surgery was considered the start date of treatment. A total of 386 patients with wild-type BRCA or not tested for BRCA mutations and 79 patients with documented BRCA mutations fit the above-described parameters and were included in the two survival analyses.
Neoadjuvant chemotherapy cohort
Women with EOC who received neoadjuvant platinum-based chemotherapy followed by cytoreductive surgery at the YNHH between 1996 and 2010 were identified on an International Review Board-approved protocol (n ¼ 125) (Supplementary Table 5 ). This cohort of patients received chemotherapy as a primary treatment due to tumor burden that was too extensive for optimal surgical debulking at presentation. After chemotherapy, patients underwent cytoreductive surgery and additional adjuvant treatment. Only patients treated with four or more cycles of neoadjuvant platinum-containing combinations were included in this analysis (n ¼ 116). Optimal cytoreduction was defined as residual disease measuring o1 cm remaining after surgery, whereas suboptimal cytoreduction was defined as residual disease measuring X1 cm at the completion of surgery. Only women operated on at Yale by the same group of surgeons were included to avoid bias in surgical skill as a factor impacting residual disease.
Patients for analysis of platinum resistance Platinum resistance was defined as progression-free survival of o6 months from the completion of platinum-containing adjuvant chemotherapy to the date of recurrence. The progression-free survival interval was available from women from Italy #1, Italy #2 and the YNHH patients (n ¼ 291). Supplementary Table 6 describes the clinicopathological parameters of these patients.
Detection of the KRAS variant DNA was isolated using standard methods from tumor, blood or saliva. As previously shown, 13 the KRAS variant does not appear to be somatically acquired nor does it require a loss of heterozygosity; hence, each of these tissues are appropriate to test and the results are identical regardless of the tissue tested. 13 The variant allele was detected using a primer specific to the KRAS variant and a TaqMan (Applied Biosystems, Foster City, CA, USA) PCR assay on all samples. Genotyping was performed at the YNHH, except for on samples from COH, for which the genotyping was performed in their facility. Less than 3% of populations carry 2 copies of the variant. 13 As such, patients who carried at least one copy of the variant allele were classified as KRAS-variant carriers.
Gene expression analysis of EOC with and without the KRAS variant
Gene expression in fresh-frozen tumor samples obtained from 16 patients (9 non-variant and 7 KRAS variant) was profiled on the Affymetrix GeneChip Human Genome U133 Plus 2.0 platform (Affymetrix, Santa Clara, CA, USA). All samples were from high-grade serous epithelial ovarian tumors that were stage IIIC or IV. Images were processed with the MAS5 algorithm and probes that were judged absent in at least 75% of the samples were removed. Intensity values were log transformed and quantile normalized. Differential gene expression was assessed in samples obtained from patients over 52 years of age (n ¼ 6 non-variant and 4 KRAS variant) using a linear model and empirical Bayesian error moderation as implemented in the LIMMA package for R statistical software (R Foundation for Statistical Computing (http://www.r-project.org)). 29 Association of previously published results with the KRAS variant in our data set was assessed using a signature approach to reduce cross-platform effects. 15 In brief, signature scores were computed as Pearson's correlation between the respective signature vector of gene contributions and each sample's expression profile for these genes. Differences between signature scores in KRAS-variant and non-variant EOC samples were assessed using the paired Kolmogorov --Smirnov test. Unless otherwise indicated, gene lists from the respective publications were used as signature vectors. Data from the study by Peters et al. 20 were obtained from the Gene Expression Omnibus (GSE1926) and re-analyzed to generate a signature from the 50 most significantly differentially expressed genes between platinumsensitive and resistant samples.
Chemosensitivity/cell viability assays
The activity of drugs alone or in combination was determined by a highthroughput CellTiter-Blue cell viability assay. For these assays, 1.2 Â 10 3 cells were plated in each well of 384-well plates using a Precision XS liquid handling station (Bio-Tek Instruments Inc., Winooski, VT, USA) and allowed to attach overnight with incubation at 37 1C, 5% CO 2 . Using the liquidhandling station, all drugs were serially diluted 2:3 or 1:2 in media, and 5 ml of these dilutions were added to appropriate wells at indicated times. Four replicate wells were used for each drug concentration and an additional four control wells received a diluent control without drug. At the end of the incubation period with drugs, 5 ml CellTiter-Blue reagent (Promega Corp., Madison, WI, USA) was added to each well. Cell viability was assessed by the ability of the remaining viable cells to bioreduce resazurin to resorufin. The fluorescence of resorufin (579 nm Ex/584 nm Em) was measured using a Synergy 4 microplate reader (Bio-Tek Instruments Inc.). The fluorescence data were transferred to Microsoft Excel (Microsoft) to calculate the percentage viability relative to the four replicate cell wells that did not receive the drug. IC50s were determined using a sigmoidal equilibrium model regression using XLfit version 5.2 (ID Business Solutions Ltd). The IC50 was defined as the concentration of drug required for a 50% reduction in growth/viability. All experiments were carried out a minimum of three times.
Targeting the KRAS variant Small-interfering RNA sequences were designed to target the KRAS-variant sequence by placing the single-nucleotide polymorphism at varying positions of the 6 nucleotides at the 5 0 end of the siRNA guide strand corresponding to the so-called 'seed sequence'. Blast searches were performed to minimize cross-reactivity. In some of the siRNA sequences, DNA nucleotides were introduced to optimize thermoenergetic features for preferred incorporation of the guide strand into the argonaute effector complex or to increase specificity for the variant.
Small-interfering RNA guide strand sequences used in the experiments are as follows (lower case ¼ RNA, upper case ¼ DNA; GS ¼ guide strand, PS ¼ passenger strand):
2-1 GS ugcaucacuugaggucaggag 2-1 PS ccugaccucaagugaugcacc 2-3 GS TGCATCACuugaggucaggag (passenger strand same as 2-1) 3-2 GS ucaucacuugaggucaggagu 3-2 PS uccugaccucaagugaugcac The negative control used was purchased from Qiagen (Valencia, CA, USA) (AllStars Negative-Control siRNA). Knockdown efficiency and specificity to the KRAS variant of these sequences were confirmed using a dual luciferase assay (data not shown). Oligonucleotide combinations were annealed using standard conditions and then transfected into cells using standard protocols. Cell survival was assayed using MTT assays and experiments were conducted in quadruplicate, and repeated in four independent experiments for all lines. Cell lysates were collected 72 h after transfection and KRAS protein levels measured by western analysis using a probe specific to KRAS as described previously. 13 
Statistics
To assess the significance of demographic variables, a w 2 test or a twosided Fisher's exact test was used for categorical variables. A t-test was used for continuous variables, such as age.
The overall survival time of KRAS-variant and wild-type patients was compared using the Kaplan --Meier method, 30 and the statistical significance of the survival curves was determined by the log-rank test. 31 A Cox proportional hazards regression model 32 was used to assess the impact of the KRAS variant and demographic and prognostic variables (such as age, stage, grade and histology) on overall survival.
Multivariate logistic regression analyses 33 were used to determine the impact of the KRAS variant and other demographic and prognostic factors on the probability of suboptimal cytoreduction. Multivariate logistic regression analyses 33 were used to assess the association of the KRAS variant and other prognostic factors on the probability of platinum resistance.
All statistical analyses were performed using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA) and in R 2.12.1 (R Foundation for Statistical Computing).
